Paul Streck, MD, Head of R&D, commented, “As of January 23, 2025, all treatment related adverse events in CONNECT1 have been mild, and we believe that the emerging safety profile of PGN-EDO51 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback